URELLE TABLET
FDA nonproprietary name: hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate
For 30 tablets
Pharmacies pay
$282.95 filed
30 × $9.4315 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01 · as of 2026-10-14 · retrieved 2026-10-17
Medicare
We don’t know yet
No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.
The spread
We don’t know yet
There is no Medicare figure to compare with, so there is no spread.
Cost-plus estimate
$330.39 estimated
$282.95 + $42.44 (15%) + $5.00 fee per fill = $330.39
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-01-01 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
URELLE TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate, under the trade name “URELLE”.
FDA gives its dosage form as tablet and its route as oral.
The labeler, the company named on the label, is Viatris Specialty LLC.
FDA’s Established Pharmacologic Class for it is Oxidation-Reduction Agent.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00037-6321-90.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $282.95 for 30 tablets (30 × $9.4315 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-01-01. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 4, carried forward from the previous file; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.
This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-01. The file is new; the price is not.
What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices
The NDC
- 00037-6321-90 · Viatris Specialty LLC · $9.4315 per EA · eff. 2026-01-01 filed carried forward
Compared with its class
Its NADAC price is $9.4315 per EA filed.
Of the 3 other products in FDA’s Oxidation-Reduction Agent class priced per EA, 0 have a higher middle NADAC price and 3 a lower one. The one in the middle is ME-NAPHOS-MB-HYO 1 TABLET, at $3.97609 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
We don’t know yet; the card above says why.
Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.